Department of Haematology,Imperial College Academic Health Science Centre, Hammersmith Hospital, Du Cane Rd., London, UK.
Br J Haematol. 2011 Apr;153(2):179-90. doi: 10.1111/j.1365-2141.2011.08603.x. Epub 2011 Mar 8.
Molecular testing for the BCR-ABL1 fusion gene by real time quantitative polymerase chain reaction (RT-qPCR) is the most sensitive routine approach for monitoring the response to therapy of patients with chronic myeloid leukaemia. In the context of tyrosine kinase inhibitor (TKI) therapy, the technique is most appropriate for patients who have achieved complete cytogenetic remission and can be used to define specific therapeutic milestones. To achieve this effectively, standardization of the laboratory procedures and the interpretation of results are essential. We present here consensus best practice guidelines for RT-qPCR testing, data interpretation and reporting that have been drawn up and agreed by a consortium of 21 testing laboratories in the United Kingdom and Ireland in accordance with the procedures of the UK Clinical Molecular Genetics Society.
实时定量聚合酶链反应 (RT-qPCR) 检测 BCR-ABL1 融合基因是监测慢性髓系白血病患者治疗反应最敏感的常规方法。在酪氨酸激酶抑制剂 (TKI) 治疗的情况下，该技术最适用于已达到完全细胞遗传学缓解的患者，可用于定义特定的治疗里程碑。为了有效地实现这一目标，实验室程序的标准化和结果的解释至关重要。我们在此介绍了由英国和爱尔兰的 21 个检测实验室组成的联盟根据英国临床分子遗传学学会的程序制定并达成一致的 RT-qPCR 检测、数据解释和报告的共识最佳实践指南。
